首页 | 本学科首页   官方微博 | 高级检索  
检索        

西地那非治疗高海拔地区儿童先天性心脏病并发重度肺动脉高压的临床研究
引用本文:李毅,谢新权.西地那非治疗高海拔地区儿童先天性心脏病并发重度肺动脉高压的临床研究[J].现代药物与临床,2015,30(7):837-840.
作者姓名:李毅  谢新权
作者单位:阿坝藏族羌族自治州人民医院儿科,四川阿坝,624000
摘    要:目的探讨西地那非治疗高海拔地区儿童先天性心脏病并发重度肺动脉高压的临床疗效。方法选择2012年1月—2014年12月阿坝藏族羌族自治州人民医院儿科收治的先天性心脏病合并重度肺动脉高压患儿150例,随机分为对照组和治疗组,每组各75例。对照组采用常规方法治疗,治疗组在常规治疗基础上口服枸橼酸西地那非片,0.3 mg/kg,3次/d。两组均连续治疗7 d。观察两组的临床疗效,同时比较两组治疗前后N末端脑钠肽(NT-pro BNP)、C反应蛋白(CRP)、肺循环阻力指数(PVRI)、每分心输出量(CO)、氧合指数(OI)、肺动脉收缩压(PASP)、平均肺动脉压(m PAP)、血氧分压(PaO_2)、心指数(CI)、呼吸困难评分的变化。结果治疗后,对照组和治疗组的总有效率分别为69.3%、92.0%,两组总有效率比较差异有统计学意义(P0.05)。治疗后,两组患者呼吸困难评分、NT-Pro BNP、CRP、m PAP、PASP均显著降低,PaO_2、OI、CI、PVRI、CO显著升高,同组治疗前后差异有统计学意义(P0.05);且治疗组这些观察指标的观察程度优于对照组,两组比较差异有统计学意义(P0.05)。结论西地那非治疗高海拔地区儿童先天性心脏病合并重度肺动脉高压临床疗效较好,可降低肺动脉阻力,改善肺循环血流动力学指标,具有较高的安全性和可靠性,值得在临床推广应用。

关 键 词:枸橼酸西地那非片  先天性心脏病  重度肺动脉高压  高原地区  儿童
收稿时间:2015/3/26 0:00:00

Clinical study on sildenafil in treatment of high altitude congenital heart disease in children complicated with severe pulmonary hypertension
LI Yi and XIE Xin-quan.Clinical study on sildenafil in treatment of high altitude congenital heart disease in children complicated with severe pulmonary hypertension[J].Drugs & Clinic,2015,30(7):837-840.
Authors:LI Yi and XIE Xin-quan
Institution:Department of Pediatrics, People's Hospital of Aba Tibetan and Qiang Autonomous Prefecture, Aba 624000, China;Department of Pediatrics, People's Hospital of Aba Tibetan and Qiang Autonomous Prefecture, Aba 624000, China
Abstract:objective To investigate the efficacy of sildenafil in treatment of high altitude congenital heart disease in children complicated with severe pulmonary hypertension. Methods Patients (150 cases) with congenital heart disease in children complicated with severe pulmonary hypertension in Department of Pediatrics of People's Hospital of Aba Tibetan and Qiang Autonomous Prefecture from January 2012 to December 2014 were randomly divided into control and treatment groups. Each group had 75 cases. Patients in control group were given conventional treatment. Patients in treatment group were po administered with Sildenafil Citrate Tablets on the basis of the control group, 0.3 mg/kg, three times daily. Two groups were treated for 7 d. After treatment, the efficacy was evaluated, and the changes of NT-proBNP, CRP, PVRI, CO, OI, PASP, mPAP, PaO2, CI, and dyspnea score in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 69.3% and 92.0%, respectively, and there were differences between two groups (P < 0.05). After treatment, dyspnea score, NT-ProBNP, CRP, mPAP, and PASP in two groups were significantly reduced, while PaO2, OI, CI, PVRI, and CO in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Conclusion Sildenafil has clinical curative effect in treatment of high altitude congenital heart disease in children complicated with severe pulmonary hypertension, can reduce pulmonary artery resistance, and can significantly improve the hemodynamic parameters about pulmonary circulation with high safety and reliability, which is worth popularizing in clinical application.
Keywords:Sildenafil Citrate Tablets  congenital heart disease  severe pulmonary hypertension  high altitude  children
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号